Can PFS predict treatment-related overall survival in MCL?
Researchers conducted a systematic review of phase III trials to assess the correlation between these two endpoints in MCL studies. The final analysis
Mantle Cell Lymphoma
News
Acute Myeloid Leukemia
Myelodysplastic Syndromes
News
Gene editing technology may improve toxicity, efficacy of transplants for AML, MDS
The phase I/II study was conducted at 15 sites in the United States and Canada. A total of 30 adults with AML or
Indolent B-Cell Lymphomas
News
5-year BRUIN data show pirtobrutinib induces response in previously treated Waldenström macroglobulinemia
Pirtobrutinib resulted in an 82.5% objective response rate in patients with Waldenström macroglobulinemia, and the ORR was 81.0% in those who previously received
Leukemia
Ingredient in popular energy drinks linked to leukemia growth
Taurine, an ingredient found in popular energy beverages like Red Bull, may promote leukemogenesis, according to findings published in Nature by Sonali Sharma,
Cellular Therapy
Leukemia
Acute Lymphoblastic Leukemia
News
Fractionated var-cel induces deep remissions, has low incidence of CRS in patients with B-ALL
Var-cel was approved in 2021 in Spain for patients ages 25 years and older with relapsed or refractory B-cell precursor ALL.
Multiple Myeloma
Clinical trial criteria exclude over 40% of real-world patients with AL amyloidosis
In a letter published in HemaSphere, Claudia Bellofiore, MD, of the University of Pavia in Italy, and colleagues highlighted the need to expand
Multiple Myeloma
Myeloproliferative Neoplasms
News
Smoldering MM trends data show increased incidence in certain patient populations
A Letter to the Editor published in the American Journal of Hematology by Rong Wang, PhD, of Yale University, and colleagues is the
Lymphoma
Aggressive B-Cell Lymphomas
News
Study shows PRO data are important component of treatment efficacy, tolerability assessment
Researchers used data from the POLARIX study to compare patient-reported outcomes (PROs) against clinician-reported adverse event (AE) data and found that several AEs
Cellular Therapy
Multiple Myeloma
News
Talquetamab, teclistamab combo induces responses in patients with extramedullary myeloma
“These results show clinical benefit from this off-the-shelf, bispecific antibody combination and validate dual targeting of GPRC5D and BCMA with talquetamab plus teclistamab
Leukemia
Lymphoma
News
Pirtobrutinib significantly improves PFS in patients with treatment-naïve CLL/SLL
Data from a late-breaking abstract presented by Wojciech Jurczak, MD, PhD, of the Maria Sklodowska-Curie National Research Institute of Oncology in Poland, at